StockGuru Blog: The Immune Response Corporation – FOXP3+ Highlighted in latest issue of Scientific American
Offers validation for IMNR’s novel autoimmune disease technology; success in clinical trials could favorably impact Product Pipeline IMNR - The Immune Response Corporation StockGuru Profile IMNR The Immune Response Corporation (OTCBB:IMNR), is an immuno-pharmaceutical company. Stock Guru has scheduled several interviews with IMNR’s scientists and officers. A large NeuroVax(TM) trial, to start imminently, will provide the opportunity to further explore the FOXP3+ regulatory T-cell mechanism of action that was demonstrated in IMNR’s Phase IIa trial data presented this past April at AAN. As evidenced by the article entitled “Peacekeepers of the Immune System” in the latest issue of Scientific American,…